| 002486-I | A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Common Variable Immunodeficiency | Participants currently recruited/enrolled | 12-75 Years | NIAID | | 002480-I | A Phase 2 Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis | Participants currently recruited/enrolled | 2-75 Years | NIAID | | 002425-I | VRC 329: A Phase I Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (STEMos1) with and without ALFQ Adjuvant in Healthy Adults | Participants currently recruited/enrolled | 18-50 Years | NIAID | | 002421-I | Rechallenge with a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged with H10N7 Influenza | Recruitment has not started | 18-55 Years | NIAID | | 002409-I | Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of BPL-1357 against H1N1 Influenza Virus Challenge | Recruitment has not started | 18-55 Years | NIAID | | 002385-I | Base Editing Hematopoietic Stem Cell and BE T Cell Gene Therapy for CD40L-HyperIgM Syndrome-Single Patient Study | Participants currently recruited/enrolled | 37-120 Years | NIAID | | 002313-I | Use of the Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans with Dysphagia in Mali and the United States | Participants currently recruited/enrolled | 18-65 Years | NIAID | | 002305-I | An Intermediate Patient Population Expanded Access Protocol for MBP091 for Patients with Marburg Virus Disease (MVD) | Enrolling by Invitation | 2-120 Years | NIAID | | 002302-I | A Pilot Prospective Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter Pylori | Participants currently recruited/enrolled | 18-99 Years | NIAID | | 002295-I | A Study to Evaluate Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART | Enrolling by Invitation | 18-70 Years | NIAID | | 002293-I | VRC 328: A Phase I Open-Label Clinical Trial to Evaluate the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) with and without ALFQ Adjuvant in Healthy Adults | Participants currently recruited/enrolled | 18-50 Years | NIAID | | 002288-I | Phase 1 Study of the Safety of an Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection | Participants currently recruited/enrolled | 18-29 Years | NIAID | | 002273-I | Phase 1/2 Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy | Enrolling by Invitation | 3-99 Years | NIAID | | 002257-I | THREAT: Testing Harms Related to Exposure to Allergenic and Epithelial Toxins | Recruitment has not started | 18-80 Years | NIAID | | 002223-I | An Open-Label, Single-Arm Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders | Enrolling by Invitation | 12-75 Years | NIAID | | 002211-I | Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People with HIV Receiving Antiretroviral Therapy | Participants currently recruited/enrolled | 18-75 Years | NIAID | | 002206-I | Intermediate Expanded Access Program for NT-I7 (efineptakin alfa) in Patients With Autosomal Recessive Genetic Deficiency of Interleukin-7 | Participants currently recruited/enrolled | 18-99 Years | NIAID | | 002199-I | A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Modified Ex Vivo Using Prime Editing (PM359) in Participants with Autosomal Recessive Chronic Granulomatous Disease due to Mutations in the NCF1 Gene | No longer recruiting/follow-up only | 6-100 Years | NIAID | | 002176-I | A Pilot Study to Evaluate the Safety and Tolerability of Baricitinib in Patients with Job s Syndrome with Lupus-like Disease and/or Atopic Dermatitis | Participants currently recruited/enrolled | 12-120 Years | NIAID | | 002062-I | Modeling Host-Pathogen Interaction Using Lymphoid Organoids | Participants currently recruited/enrolled | 2-120 Years | NIAID | | 001979-I | A Pilot Phase 2 Study of the Safety and Efficacy of Dupilumab as Add-on Therapy for Hypereosinophilic Syndrome with Partial Clinical Response to Eosinophil-Depleting Biologic Agents | Participants currently recruited/enrolled | 18-99 Years | NIAID | | 001976-I | A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Primary Immunodeficiency Disorders | Participants currently recruited/enrolled | 12-75 Years | NIAID | | 001970-I | Phase 1 Study of Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays | Participants currently recruited/enrolled | 18-54 Years | NIAID | | 001965-I | VRC 617: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety and Pharmacokinetics of a Human Bispecific Antibody, VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults | No longer recruiting/follow-up only | 18-60 Years | NIAID | | 001957-I | Intermediate Patient Population Expanded Access Protocol for MBP134 for Patients with Sudan Virus Disease (SVD) | Enrolling by Invitation | 2-100 Years | NIAID | | 001928-I | A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-up | Participants currently recruited/enrolled | 3-100 Years | NIAID | | 001899-I | Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study | Participants currently recruited/enrolled | 18-120 Years | NIAID | | 001867-I | A Phase 1 Study of Repeat PET/CT Imaging in People with CAPS and Anakinra-Induced Amyloidosis Using Amyloid-Reactive Peptide 124I-AT-01 (124I-p5+14, Iodine-124I-Evuzamitide) to Measure Changes in Organ-Specific Amyloid Load | Participants currently recruited/enrolled | 18-120 Years | NIAID | | 001854-I | An Open-Label Study of Zemaira (Alpha 1-Trypsin Inhibitor) in Subjects with Eosinophilic Esophagitis | Participants currently recruited/enrolled | 18-70 Years | NIAID | | 001824-I | A Phase 2a Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients | Participants currently recruited/enrolled | 16-120 Years | NIAID | | 001752-I | Primary Immune Regulatory Disorders (PIRD): Longitudinal Study of Clinical Presentation, Treatment and Outcomes | Participants currently recruited/enrolled | 0-99 Years | NIAID | | 001722-I | An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 1 to 6 Years) with APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-label Long-term Ext | No longer recruiting/follow-up only | 3-6 Years | NIAID | | 001716-I | Analysis of Autoinflammation in Chronic Granulomatous Disease Patients Undergoing Hematopoietic Cell Transplant or Gene Therapy RDCRN - PIDTC 6908 | Participants currently recruited/enrolled | 4-65 Years | NIAID | | 001706-I | A Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Naive Adults | Participants currently recruited/enrolled | 18-45 Years | NIAID | | 001677-I | A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial of Cardamom and Topical Roseomonas in Atopic Dermatitis | Participants currently recruited/enrolled | 2-100 Years | NIAID | | 001658-I | Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts | Participants currently recruited/enrolled | 3-80 Years | NIAID | | 001631-I | An Exploratory Study of The Effect of Bismuth Subsalicylate on The Gut Microbiome and Host Response in Healthy Adults | Completed Study; data analyses ongoing | 18-50 Years | NIAID | | 001614-I | VRC 326 (001614): A Phase I Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults | Completed Study; data analyses ongoing | 18-50 Years | NIAID | | 001580-I | Phase 1/2 Trial of Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-linked Chronic Granulomatous Disease | Participants currently recruited/enrolled | 18-75 Years | NIAID | | 001573-I | An Open-Label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) With APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-Label Long-Term Ex | No longer recruiting/follow-up only | 4-11 Years | NIAID | | 001562-I | A Phase I/II, Non-Randomized, Open-Label Study of pCCLCHIM-p47 (Lentiviral Vector Transduced CD34+ Cells) in Patients with p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD) | Enrolling by Invitation | 3-65 Years | NIAID | | 001511-I | Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity | Participants currently recruited/enrolled | 2-120 Years | NIAID | | 001501-I | Phase 1 Dose Escalation Study of The Plasmodium Vivax Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-Blocking Activity in Healthy Malaria-Naive Adults | Completed Study; data analyses ongoing | 18-50 Years | NIAID | | 001146-I | A Repository to Study Host-Microbiome Interactions in Health and Disease | Participants currently recruited/enrolled | 0-125 Years | NIAID | | 001078-I | Phase 1 Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine | No longer recruiting/follow-up only | 18-59 Years | NIAID | | 001048-I | A Phase 1/2 Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-Seronegative Persons | No longer recruiting/follow-up only | 18-25 Years | NIAID | | 001043-I | Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders | Participants currently recruited/enrolled | 0-99 Years | NIAID | | 001037-I | A Randomized Placebo-controlled Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living with HIV and on Suppressive Antiretroviral Therapy | No longer recruiting/follow-up only | 18-70 Years | NIAID | | 000977-I | Phase I/II Study using Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease with an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined with Cytokine (IL-6, +/- IFN-gamma) Antagonists | Participants currently recruited/enrolled | 4-65 Years | NIAID | | 000906-I | A Phase 2 Randomized Cross-Over Design Study of the Early Metabolic Effects of Dolutegravir or Tenofovir Alafenamide in Healthy Volunteers | Participants currently recruited/enrolled | 18-55 Years | NIAID | | 000866-I | Phase 1/2 Open-label Trial of Safety and Zoster Immunogenicity Evaluation for people with HIV with CD4 counts Under and Above 300 and Healthy Volunteers following Shingrix Vaccination (ZEUS) | Participants currently recruited/enrolled | 18-125 Years | NIAID | | 000861-I | A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients with Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata | Participants currently recruited/enrolled | 12-75 Years | NIAID | | 000821-I | An Open-Label, Single-Arm, Phase 1/2 Dose-Escalation Trial of Long-Acting Recombinant Human IL-7 (NT-I7, Efineptakin-Alpha) for Idiopathic CD4 Lymphopenia | Participants currently recruited/enrolled | 18-75 Years | NIAID | | 000809-I | A Pilot Study of Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis | Participants currently recruited/enrolled | 10-60 Years | NIAID | | 000707-I | Respiratory Virus Sampling and Repository | Participants currently recruited/enrolled | 3-125 Years | NIAID | | 000688-I | Longitudinal Observations of Vaccine Responses to SARS-CoV-2 and other Emerging Infectious Diseases | Participants currently recruited/enrolled | 18-125 Years | NIAID | | 000609-I | Pilot Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD) | No longer recruiting/follow-up only | 4-65 Years | NIAID | | 000488-I | Natural History of Systemic and Nasal Mucosal Immunity after Influenza Vaccination in a Pediatric Population | Completed Study; data analyses ongoing | 2-17 Years | NIAID | | 000460-I | A Randomized, Placebo-controlled Crossover Study to Assess the Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose | Completed Study; data analyses ongoing | 16-69 Years | NIAID | | 000392-I | Metabolic Profiling of Immune Responses in Immune-Mediated Diseases | Participants currently recruited/enrolled | 18-75 Years | NIAID | | 000331-I | Investigating the Human Immune Response to Ixodes scapularis Tick Bites | Participants currently recruited/enrolled | 18-99 Years | NIAID | | 000291-I | Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies | Participants currently recruited/enrolled | 18-65 Years | NIAID | | 000281-I | Pilot Assessment To Find Evidence of Gastric Motility Abnormalities in Eosinophilic Gastric Disorders | Participants currently recruited/enrolled | 18-59 Years | NIAID | | 000256-I | Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults after Vaccination | Participants currently recruited/enrolled | 18-120 Years | NIAID | | 000226-I | Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy | Participants currently recruited/enrolled | 18-75 Years | NIAID | | 000212-I | Induced Blood-Stage Plasmodium Vivax Infection with HMPBS02-Pv Challenge Agent in Healthy Malaria-Naive Adults to Produce a Plasmodium Vivax Parasite Cell Bank for Future Studies | Completed Study; data analyses ongoing | 18-50 Years | NIAID | | 000201-I | Pediatric SARS-CoV-2 and MIS-C Long-term Follow-up | Participants currently recruited/enrolled | 0-21 Years | NIAID | | 000186-I | Part B- Phase I/II, Non-Randomized, Single site study, Open-label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients with X-Linked Chronic Granulomatous Disease | Enrolling by Invitation | 3-60 Years | NIAID | | 000064-I | A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease with Inflammatory Complications | Enrolling by Invitation | 18-99 Years | NIAID | | 22-I-0001 | NADPH Oxidase Correction in mRNA transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD) | Participants currently recruited/enrolled | 18-75 Years | NIAID | | 21-I-0029 | Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune) | Participants currently recruited/enrolled | 3-125 Years | NIAID | | 21-I-0005 | Phase 1 Study of the Safety and Immunogenicity of an Epstein-Barr virus (EBV) gp350- Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection | No longer recruiting/follow-up only | 18-29 Years | NIAID | | 20-I-0160 | Dose-Escalation Study of a Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model | Completed Study; data analyses ongoing | 18-50 Years | NIAID | | 20-I-0132 | A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES) | No longer recruiting/follow-up only | 12-130 Years | NIAID | | 20-I-0123 | A Longitudinal Study of COVID-19 Sequelae and Immunity | No longer recruiting/follow-up only | 18-120 Years | NIAID | | 20-I-0111 | COVID-19-Associated Lymphopenia Pathogenesis Study in Blood | Completed Study; data analyses ongoing | 18-99 Years | NIAID | | 20-I-0084 | Sample Collection for Systems Evaluation of Patients with Unknown or Incompletely Characterized Immune Defects | Completed Study; data analyses ongoing | 2-120 Years | NIAID | | 19-I-0140 | A Phase 1 Evaluation of the Safety of Belimumab in People with Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe) | Participants currently recruited/enrolled | 18-70 Years | NIAID | | 19-I-0133 | Paradoxical Tuberculosis Reactions in Patients without HIV Infection | Participants currently recruited/enrolled | 18-99 Years | NIAID | | 19-I-0126 | Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine | Completed Study; data analyses ongoing | 18-125 Years | NIAID | | 19-I-0108 | Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients with Chronic Granulomatous Disease | Completed Study; data analyses ongoing | 8-65 Years | NIAID | | 19-I-0093 | Collection of Human Biospecimens for Basic and Clinical Research into Globin Variants | Participants currently recruited/enrolled | 18-70 Years | NIAID | | 19-I-0080 | Haploidentical Transplant for Patients with Chronic Granulomatous Disease (CGD) using Alemtuzumab, Busulfan and TBI with Post-Transplant Cyclophosphamide | No longer recruiting/follow-up only | 4-65 Years | NIAID | | 19-I-0069 | Phase I Open-Label Study of Safety and Immunogenicity of AD4-HIV Envelope Vaccine Vectors in Healthy Volunteers | Participants currently recruited/enrolled | 18-65 Years | NIAID | | 19-I-0053 | Prospective Study to Identify Food-Specific and Component IgE Threshold Levels that Predict Food Allergy in Patients with Elevated Total Serum IgE Levels and Atopic Dermatitis | Participants currently recruited/enrolled | 3-21 Years | NIAID | | 19-I-0022 | A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EoG), Enteritis (EoN) and Colitis (EoC) | Participants currently recruited/enrolled | 3-125 Years | NIAID | | 19-I-0003 | A Multicenter, Multi-Outbreak, Randomized, Controlled Safety and Efficacy Study of Investigational Therapeutics for the Treatment of Patients with Ebola Virus Disease | Completed Study; data analyses ongoing | 0-99 Years | NIAID | | 18-I-0139 | Defining Skin Immunity of a Bite of Key Insect Vectors in Humans | Completed Study; data analyses ongoing | 18-64 Years | NIAID | | 18-I-0128 | Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies | Participants currently recruited/enrolled | 0-99 Years | NIAID | | 18-I-0101 | Sample Collection From Healthy Volunteers for Assay Optimization | Participants currently recruited/enrolled | 3-80 Years | NIAID | | 18-I-0092 | A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients with Idiopathic CD4 T cell Lymphocytopenia | No longer recruiting/follow-up only | 18-70 Years | NIAID | | 18-I-0041 | Investigating the Mechanistic Biology of Primary Immunodeficiency Disorders | Participants currently recruited/enrolled | 0-90 Years | NIAID | | 18-I-0039 | Challenge Infection of Healthy Adult Volunteers with RSV A2 | Completed Study; data analyses ongoing | 18-50 Years | NIAID | | 18-I-0030 | VRC 603: A Phase 1 Dose-Escalation Study of the Safety of AAV8-VRC07 (VRC-HIVAAV070-00-GT) Recombinant AAV Vector Expressing VRC07 HIV-1 Neutralizing Antibody in Antiretroviral-Treated, HIV-1 Infected Adults with Controlled Viremia | No longer recruiting/follow-up only | 18-65 Years | NIAID | | 18-I-0022 | Use of Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients with Leukocyte Adhesion Deficiency Type 1 (LAD1) who have Inflammatory Pathology | Completed Study; data analyses ongoing | 12-65 Years | NIAID | | 17-I-0122 | NIAID Centralized Sequencing Protocol | Participants currently recruited/enrolled | 0-100 Years | NIAID | | 17-I-0101 | An Open-Label, Proof of Concept Study of Vorinostat for the Treatment of Moderate-to-Severe Crohn's Disease and Maintenance Therapy with Ustekinumab | Participants currently recruited/enrolled | 18-65 Years | NIAID | | 17-I-0083 | Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) | Participants currently recruited/enrolled | 18-120 Years | NIAID | | 17-I-0072 | Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA) | Completed Study; data analyses ongoing | 18-99 Years | NIAID | | 17-I-0067 | Sanaria(R) PfSPZ Challenge with Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Dose Escalation Trial to Determine Safety and Development of Protective Efficacy after Exposure to Only Pre-erythrocytic Stages of Plasmodium falciparum | Completed Study; data analyses ongoing | 18-50 Years | NIAID | | 17-I-0016 | Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's-like Diseases, and Other Undifferentiated Autoinflammatory Diseases) | Participants currently recruited/enrolled | 0-99 Years | NIAID | | 16-I-0078 | Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME study) | Completed Study; data analyses ongoing | 18-49 Years | NIAID | | 16-I-0065 | Screening for Alpha Globin Deletions | No longer recruiting/follow-up only | 18-39 Years | NIAID | | 16-I-0053 | A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSVdeltaG-ZEBOV GP) for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebola Virus Exposure (PREPARE) | Completed Study; data analyses ongoing | 18-75 Years | NIAID | | 16-I-0039 | Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge | Participants currently recruited/enrolled | 18-50 Years | NIAID | | 16-I-0032 | High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous Disease | No longer recruiting/follow-up only | 4-65 Years | NIAID | | 15-I-0162 | Natural History and Genetics of Food Allergy and Related Conditions | Participants currently recruited/enrolled | 0-99 Years | NIAID | | 15-I-0154 | Long-Term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge | Enrolling by Invitation | 18-120 Years | NIAID | | 15-I-0148 | A Phase I Study of Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers | Completed Study; data analyses ongoing | 18-50 Years | NIAID | | 15-I-0131 | Xenodiagnosis after Antibiotic Treatment for Lyme Disease - Phase II Study | Completed Study; data analyses ongoing | 18-125 Years | NIAID | | 14-I-0206 | Novel Genetic Disorders of the Immune System | Participants currently recruited/enrolled | 3-99 Years | NIAID | | 14-I-0146 | The Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis | Participants currently recruited/enrolled | 2-100 Years | NIAID | | 14-I-0124 | PET Imaging and Lymph Node Assessment of IRIS in Persons With AIDS | Participants currently recruited/enrolled | 18-100 Years | NIAID | | 14-I-0091 | Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995 | Completed Study; data analyses ongoing | 3-125 Years | NIAID | | 14-I-0081 | A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Benralizumab (MEDI-563) in Reducing Eosinophilia in Subjects with Hypereosinophilic Syndrome (HES) | No longer recruiting/follow-up only | 18-75 Years | NIAID | | 14-I-0063 | An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects with Hypereosinophilic Syndrome | No longer recruiting/follow-up only | 18-125 Years | NIAID | | 14-I-0020 | Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models | Participants currently recruited/enrolled | 18-65 Years | NIAID | | 13-I-0172 | Phase I Study of the Safety of a Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection | Completed Study; data analyses ongoing | 18-40 Years | NIAID | | 13-I-0157 | The Natural History of GATA2 Deficiency and Related Disorders | Participants currently recruited/enrolled | 2-100 Years | NIAID | | 13-I-0082 | Rituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated Diseases | Completed Study; data analyses ongoing | 18-99 Years | NIAID | | 13-I-0062 | A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects | Completed Study; data analyses ongoing | 18-65 Years | NIAID | | 12-I-0103 | Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine | Completed Study; data analyses ongoing | 21-45 Years | NIAID | | 11-I-0187 | The Natural History and Pathogenesis of Human Fungal Infections | Participants currently recruited/enrolled | 0-99 Years | NIAID | | 11-I-0183 | Screening for LID Clinical Studies Unit Healthy Volunteer Protocols | Participants currently recruited/enrolled | 18-65 Years | NIAID | | 11-I-0164 | VRC 500: Screening Volunteers for Clinical Trials of Investigational Products and Licensed Products Evaluated for Research Purposes | Participants currently recruited/enrolled | 18-60 Years | NIAID | | 11-I-0109 | Viral Infections in Healthy and Immunocompromised Hosts | Participants currently recruited/enrolled | 0-120 Years | NIAID | | 11-I-0057 | Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy | Completed Study; data analyses ongoing | 18-65 Years | NIAID | | 11-I-0007 | Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined Immunodeficiency | Participants currently recruited/enrolled | 2-50 Years | NIAID | | 10-I-0216 | Studies of Disorders with Increased Susceptibility to Fungal Infections | Participants currently recruited/enrolled | 0-125 Years | NIAID | | 10-I-0197 | Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases | Participants currently recruited/enrolled | 2-99 Years | NIAID | | 10-I-0195 | Natural History of Tuberculosis | Participants currently recruited/enrolled | 2-100 Years | NIAID | | 10-I-0148 | Natural History of Severe Allergic Inflammation and Reactions | Completed Study; data analyses ongoing | 2-80 Years | NIAID | | 10-I-0139 | Searching for Persistence of Infection in Lyme Disease | Completed Study; data analyses ongoing | 18-125 Years | NIAID | | 10-I-0109 | VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older | Participants currently recruited/enrolled | 18-120 Years | NIAID | | 10-I-0014 | The Natural History of Severe Viral Infections and Characterization of Immune Defects | Participants currently recruited/enrolled | 2-100 Years | NIAID | | 09-I-0200 | A Phase I Study of MozobilTM in the Treatment of Patients with WHIMS | Participants currently recruited/enrolled | 18-75 Years | NIAID | | 09-I-0133 | Establishing Fibroblast-derived Cell Lines from Skin/Tissue Biopsies of Patients with Immunodeficiency or Immunodysregulation Disorders | Enrolling by Invitation | 2-85 Years | NIAID | | 09-I-0126 | Pathogenesis and Genetic Basis of Physical Induced Urticarial Syndromes | Completed Study; data analyses ongoing | 2-90 Years | NIAID | | 09-I-0102 | Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia | Participants currently recruited/enrolled | 18-125 Years | NIAID | | 09-I-0086 | Screening Protocol for Genetic Diseases of Allergic Inflammation | Completed Study; data analyses ongoing | 0-99 Years | NIAID | | 09-I-0032 | Comprehensive Multimodal Analysis of Patients with Neuroimmunological Diseases of the CNS | Participants currently recruited/enrolled | 0-99 Years | NIAID | | 09-I-0030 | Clinical and Immunologic Monitoring of Patients with Known or Suspected HIV Infection | Participants currently recruited/enrolled | 18-125 Years | NIAID | | 09-I-0013 | Biomarkers of Inflammation, Coagulation, and Endothelial Function in HIV-Infected Adults | Completed Study; data analyses ongoing | 18-100 Years | NIAID | | 08-I-0221 | Analysis of HIV-1 Replication During Antiretroviral Therapy | Enrolling by Invitation | 18-99 Years | NIAID | | 08-I-0184 | Studies in the Pathogenesis of Anaphylaxis | No longer recruiting/follow-up only | 13-75 Years | NIAID | | 07-I-0033 | Screening Protocol for Detection and Characterization of Infections and Infection Susceptibility | Participants currently recruited/enrolled | 0-100 Years | NIAID | | 06-I-0153 | A Pilot Study of Hepatic Fibrosis in HIV/AIDS Patients with Chronically Elevated Transaminases on Antiretroviral Therapy | Completed Study; data analyses ongoing | 18-100 Years | NIAID | | 06-I-0015 | Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death | Participants currently recruited/enrolled | 0-100 Years | NIAID | | 05-I-0213 | Screening and Baseline Assessment of Patients with Abnormalities of Immune Function | Participants currently recruited/enrolled | 0-125 Years | NIAID | | 04-I-0286 | A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression | Participants currently recruited/enrolled | 1-100 Years | NIAID | | 04-I-0266 | Collection of Data and Samples from Healthy Donors for Use in Translational Research | Participants currently recruited/enrolled | 18-85 Years | NIAID | | 03-I-0263 | VRC 200: A Multicenter Specimen Collection Protocol to Obtain Human Biological Samples for Research Studies | Participants currently recruited/enrolled | 3-125 Years | NIAID | | 02-I-0286 | Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome | Participants currently recruited/enrolled | 2-125 Years | NIAID | | 02-I-0277 | Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells | Participants currently recruited/enrolled | 0-80 Years | NIAID | | 02-I-0202 | Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-1 Research Participants | Participants currently recruited/enrolled | 18-120 Years | NIAID | | 02-I-0147 | Genetic Studies of Chronic Active Epstein-Barr Virus Infection | Participants currently recruited/enrolled | 1-120 Years | NIAID | | 02-I-0110 | Natural History of Anthrax: A Study of Primary Infected, Recovered, and Exposed (SPoRE) Individuals and Evaluation of AVA Vaccinated Recipients | Participants currently recruited/enrolled | 3-100 Years | NIAID | | 02-I-0086 | Evaluation of Viral Factors and Immune Parameters to Study HIV-Specific Immunity | Participants currently recruited/enrolled | 18-100 Years | NIAID | | 02-I-0080 | The Gemini Study: Study of the Long-Term Safety and Persistence of Cells Following Cell Transfers or Gene Therapy in Identical Twins Discordant for HIV Infection | Completed Study; data analyses ongoing | 18-125 Years | NIAID | | 02-I-0055 | Evaluation, Treatment, and Follow-up of Patients with Lyme Disease | Participants currently recruited/enrolled | 2-99 Years | NIAID | | 01-I-0238 | Host Response to Infection and Treatment in Leishmania Infection of Humans | Participants currently recruited/enrolled | 3-100 Years | NIAID | | 01-I-0202 | Natural History, Genetics, Phenotype, and Treatment of Mycobacterial Infections | Participants currently recruited/enrolled | 0-100 Years | NIAID | | 00-I-0159 | Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES) | Participants currently recruited/enrolled | 0-120 Years | NIAID | | 99-I-0084 | Studies of Human Pneumocystis Infection | Completed Study; data analyses ongoing | 3-99 Years | NIAID | | 97-I-0096 | Evaluation, Treatment, and Monitoring of Patients With Known or Suspected Parasitic Infection | Participants currently recruited/enrolled | 3-125 Years | NIAID | | 96-I-0052 | A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients with Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations | Participants currently recruited/enrolled | 13-99 Years | NIAID | | 95-I-0066 | Genetic Analysis of Immune Disorders | Participants currently recruited/enrolled | 0-101 Years | NIAID | | 95-I-0027 | Virologic and Immunologic Evaluation of Lymph Node, Tonsillar and Intestinal Biopsies, and Bronchoalveolar Lavage Fluid | Participants currently recruited/enrolled | 18-100 Years | NIAID | | 94-I-0079 | Eosinophil Activation and Function in Parasitic Infections and Other Conditions with Increased Tissue or Peripheral Blood Eosinophilia in Humans | Participants currently recruited/enrolled | 1-100 Years | NIAID | | 94-I-0073 | Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes | Participants currently recruited/enrolled | 18-70 Years | NIAID | | 93-I-0119 | Detection and Characterization of Host Defense Defects | Participants currently recruited/enrolled | 0-100 Years | NIAID | | 93-I-0106 | Cryptococcosis in Previously Healthy Adults | Participants currently recruited/enrolled | 18-99 Years | NIAID | | 93-I-0086 | Evaluation and Long-Term Follow-Up of Patients with Acute or Chronic Inflammatory Disorders | Enrolling by Invitation | 2-125 Years | NIAID | | 93-I-0063 | Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T Cells | Participants currently recruited/enrolled | 0-99 Years | NIAID | | 92-I-0125 | A Study of Viral Burden in Peripheral Blood versus Lymphoid and Bone Marrow Tissue in People living with HIV | Participants currently recruited/enrolled | 18-100 Years | NIAID | | 91-I-0140 | Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood cells and/or Body Fluids in People Living With and Without HIV | Participants currently recruited/enrolled | 18-120 Years | NIAID | | 89-I-0158 | Studies of Immune Regulation in Patients with Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI) | Participants currently recruited/enrolled | 2-120 Years | NIAID | | 88-I-0172 | A Phase III Study with Long-Term Follow-Up of Zidovudine Versus Zidovudine and Alpha-Interferon Versus Alpha-Interferon in Patients with Early HIV Infection | No longer recruiting/follow-up only | 18-125 Years | NIAID | | 88-I-0083 | Host Response to Infection and Treatment in the Filarial Diseases of Humans | Participants currently recruited/enrolled | 3-100 Years | NIAID | | 85-I-0127 | Natural History of Treated Neurocysticercosis and Long-Term Outcomes | Participants currently recruited/enrolled | 3-99 Years | NIAID | | 82-I-0183 | A Natural History Study of the Immune Regulation of Idiopathic Inflammatory Bowel Diseases: Crohn's Disease, Ulcerative Colitis, and Other Inflammatory Conditions of the Gut | Participants currently recruited/enrolled | 0-75 Years | NIAID | | 81-I-0164 | Procedures to Obtain Plasma, Lymphocytes, or Other Specimens for Research Studies | Participants currently recruited/enrolled | 18-100 Years | NIAID | | 78-I-0023 | Diagnosis and Management of Inflammatory and Infectious Diseases | Participants currently recruited/enrolled | 3-100 Years | NIAID | |